Phase II Multi-Centric, Randomised, Open-Label, Parallel-Group Study to Assess the Non-Inferiority of Pamorelin [triptorelin] 11,25mg SC [subcutaneous] Injected Versus Pamorelin 11,25mg IM [intramuscular] Injected in Patients Suffering From Advanced Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms PAMOJECT
- Sponsors Ipsen
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 13 Oct 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.